Pure Health Holding PJSC

PureHealth reported a net profit of AED 1.4 billion and an EBITDA of AED 3.1 billion for the first nine months of 2024. The company's consolidated revenue increased by 56% to AED 19.0 billion, primarily driven by the Hospitals segment and supported by organic growth and acquisitions. EBITDA rose by 26% compared to the same period in 2023, with an EBITDA margin of 16.5%, indicating operational efficiencies. Net profit increased by 13% year-on-year, with a net profit margin of 7.6%. Key acquisitions included Circle Health Group and Sheikh Shakhbout Medical City, while divestments included YAS Clinics Group and Abu Dhabi Stem Cells Centre. The Hospital Segment saw revenues rise by 87% and EBITDA growth of 18%, while the Insurance Segment recorded a 17% increase in revenue and a 60% growth in EBITDA. Total assets grew by 72% to AED 48.4 billion, with a cash balance of AED 8.7 billion. The net cash position was 3.0x EBITDA, with a net cash balance of AED 6.7 billion. Overall, PureHealth demonstrated strong performance and strategic growth in the first nine months of 2024.

The text refers to the interim condensed consolidated financial statements of Pure Health Holding PJSC for the period ending on September 30, 2024.

PureHealth reported a net profit of AED 1.0 billion for the first half of 2024, with EBITDA rising to AED 2.2 billion, a 15% increase from the previous year. Consolidated revenue grew by 53% to AED 12.5 billion, driven by the Hospitals segment and supported by organic growth and acquisitions. Despite the growth, net profit decreased by 26% year-on-year due to accounting changes, finance costs from acquisitions, and corporate income tax charges, resulting in a net profit margin of 8.0%. Significant acquisitions included Circle Health Group and Sheikh Shakhbout Medical City, while the company divested its investments in YAS Clinics Group and Abu Dhabi Stem Cells Centre. The Hospitals segment saw an 83% revenue increase and 9% EBITDA growth, attributed to higher patient volumes and strategic acquisitions. The Insurance vertical, comprising Daman, reported a 15% revenue increase and a 79% rise in EBITDA, driven by higher premiums and increased membership. Total assets increased to AED 47.6 billion, with a total cash balance of AED 7.4 billion and a net cash balance of AED 5.4 billion as of June 30, 2024.

Pure Health Holding PJSC has released its interim condensed consolidated financial statements for the period ending June 30, 2024.

**Summary:** PureHealth, the largest healthcare platform in the Middle East, has contributed AED 1 billion to local procurement since Q1 2023 to support the UAE's National In-Country Value (ICV) Programme. This initiative is part of the UAE's industrial strategy, aiming to boost the industrial sector's GDP contribution to AED 300 billion by 2031. During the Make it in the Emirates Forum, PureHealth confirmed its progress towards a target of AED 13 billion in local procurement by 2032. The company has also implemented ICV strategies across its operations, including subsidiaries like SEHA and Daman, achieving high ICV scores. These efforts underscore PureHealth's role in driving economic diversity, creating local jobs, and enhancing healthcare services in the UAE.

In Q1 2024, PureHealth reported a net profit of AED 491 million, a 124% increase from Q1 2023. The company's EBITDA also rose to AED 1.1 billion, a 2.3x increase from the previous year. This reflects improved operational efficiencies across all key segments. PureHealth's consolidated revenue increased by 52% to AED 6.1 billion, led by the Hospital and Other Related Services segment. The company completed the acquisition of Circle Health Group and Sheikh Shakhbout Medical City, significantly expanding its global presence. The firm's total assets increased to AED 47.3 billion, with a total cash balance of AED 8.0 billion. PureHealth's balance sheet reported a net cash balance of AED 4.4 billion as of 31 March 2024.

The text refers to the interim condensed consolidated financial statements of Pure Health Holding PJSC for the period ending on 31 March 2024. It is likely to contain financial information and performance indicators relevant to investors and those interested in the company's financial health.

The text appears to be an interim condensed consolidated financial statement from Pure Health Holding PJSC, for the period ending on 31 March 2024. These types of documents typically contain a summary of a company's financial performance over a specific period, including revenues, expenses, and net income.